SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The objective of the Post Marketing Surveillance Study is to investigate the use of the
non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy
in patients with Morbus Parkinson. Neurologists in private practices in Germany should
document the safety and course of the disease/change of parkinsonian symptoms during
stabilisation on, or change over from other dopamine agonist treatment under routine
conditions. Piribedil should be prescribed according to its marketing authorisation.